News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,853 Results
Type
Article (40733)
Company Profile (266)
Press Release (672847)
Multimedia
Podcasts (77)
Webinars (17)
Section
Business (204671)
Career Advice (2021)
Deals (35538)
Drug Delivery (101)
Drug Development (81341)
Employer Resources (174)
FDA (16342)
Job Trends (14978)
News (346271)
Policy (32726)
Tag
Academia (2562)
Accelerated approval (16)
Adcomms (24)
Allergies (116)
Alliances (49617)
ALS (136)
Alzheimer's disease (1560)
Antibody-drug conjugate (ADC) (224)
Approvals (16441)
Artificial intelligence (397)
Autoimmune disease (83)
Automation (29)
Bankruptcy (362)
Best Places to Work (11685)
BIOSECURE Act (20)
Biosimilars (154)
Biotechnology (176)
Bladder cancer (131)
Brain cancer (45)
Breast cancer (488)
Cancer (3831)
Cardiovascular disease (310)
Career advice (1703)
Career pathing (33)
CAR-T (225)
CDC (42)
Cell therapy (605)
Cervical cancer (31)
Clinical research (68261)
Collaboration (1311)
Company closure (4)
Compensation (915)
Complete response letters (44)
COVID-19 (2681)
CRISPR (73)
C-suite (564)
Cystic fibrosis (129)
Data (4637)
Decentralized trials (2)
Denatured (23)
Depression (96)
Diabetes (423)
Diagnostics (6537)
Digital health (33)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (185)
Drug pricing (159)
Drug shortages (28)
Duchenne muscular dystrophy (192)
Earnings (89010)
Editorial (47)
Employer branding (22)
Employer resources (152)
Events (115557)
Executive appointments (926)
FDA (18791)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (15)
Funding (1192)
Gene editing (159)
Generative AI (31)
Gene therapy (482)
GLP-1 (875)
Government (4618)
Grass and pollen (6)
Guidances (368)
Healthcare (18858)
HIV (43)
Huntington's disease (36)
IgA nephropathy (59)
Immunology and inflammation (213)
Immuno-oncology (17)
Indications (57)
Infectious disease (2904)
Inflammatory bowel disease (174)
Inflation Reduction Act (13)
Influenza (92)
Intellectual property (188)
Interviews (315)
IPO (16626)
IRA (48)
Job creations (3651)
Job search strategy (1431)
Kidney cancer (15)
Labor market (73)
Layoffs (537)
Leadership (28)
Legal (7950)
Liver cancer (85)
Longevity (11)
Lung cancer (552)
Lymphoma (263)
Machine learning (29)
Management (59)
Manufacturing (591)
MASH (134)
Medical device (13625)
Medtech (13649)
Mergers & acquisitions (19789)
Metabolic disorders (1039)
Multiple sclerosis (133)
NASH (16)
Neurodegenerative disease (206)
Neuropsychiatric disorders (51)
Neuroscience (2525)
NextGen: Class of 2025 (6525)
Non-profit (4497)
Now hiring (60)
Obesity (486)
Opinion (240)
Ovarian cancer (137)
Pain (152)
Pancreatic cancer (167)
Parkinson's disease (229)
Partnered (28)
Patents (406)
Patient recruitment (320)
Peanut (52)
People (58272)
Pharmaceutical (63)
Pharmacy benefit managers (26)
Phase I (21248)
Phase II (30039)
Phase III (22420)
Pipeline (2722)
Policy (249)
Postmarket research (2565)
Preclinical (9046)
Press Release (64)
Prostate cancer (191)
Psychedelics (43)
Radiopharmaceuticals (256)
Rare diseases (605)
Real estate (5944)
Recruiting (70)
Regulatory (23513)
Reports (51)
Research institute (2355)
Resumes & cover letters (351)
Rett syndrome (15)
RNA editing (12)
RSV (67)
Schizophrenia (128)
Series A (195)
Series B (149)
Service/supplier (11)
Sickle cell disease (74)
Special edition (20)
Spinal muscular atrophy (149)
Sponsored (35)
Startups (3603)
State (2)
Stomach cancer (14)
Supply chain (95)
Tariffs (84)
The Weekly (52)
Vaccines (906)
Venture capital (63)
Weight loss (317)
Women's health (55)
Worklife (17)
Date
Last 7 days (736)
Last 30 days (2465)
Last 365 days (30421)
2025 (25270)
2024 (35259)
2023 (40118)
2022 (51214)
2021 (55748)
2020 (54105)
2019 (46582)
2018 (35071)
2017 (32159)
2016 (31521)
2015 (37586)
2014 (31363)
2013 (26367)
2012 (28578)
2011 (29263)
2010 (27328)
Location
Africa (731)
Alabama (71)
Alaska (7)
Arizona (270)
Arkansas (13)
Asia (38709)
Australia (6328)
California (9315)
Canada (2845)
China (862)
Colorado (389)
Connecticut (397)
Delaware (262)
Europe (83435)
Florida (1394)
Georgia (301)
Hawaii (2)
Idaho (60)
Illinois (729)
India (48)
Indiana (451)
Iowa (18)
Japan (321)
Kansas (119)
Kentucky (34)
Louisiana (18)
Maine (68)
Maryland (1218)
Massachusetts (6785)
Michigan (283)
Minnesota (538)
Mississippi (4)
Missouri (111)
Montana (29)
Nebraska (25)
Nevada (103)
New Hampshire (72)
New Jersey (2565)
New Mexico (28)
New York (2523)
North Carolina (1253)
North Dakota (8)
Northern California (4348)
Ohio (285)
Oklahoma (20)
Oregon (37)
Pennsylvania (1957)
Puerto Rico (19)
Rhode Island (43)
South America (1103)
South Carolina (49)
South Dakota (1)
Southern California (3579)
Tennessee (149)
Texas (1438)
United States (33734)
Utah (276)
Virginia (221)
Washington D.C. (77)
Washington State (773)
West Virginia (4)
Wisconsin (79)
Wyoming (1)
713,853 Results for "abbvie inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone.
October 31, 2025
·
2 min read
·
Dan Samorodnitsky
Psychedelics
Psychedelics Space Enters New Era as AbbVie Dives In
With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.
September 22, 2025
·
6 min read
·
Heather McKenzie
Patents
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
The settlement agreement will extend market exclusivity for AbbVie’s JAK inhibitor in the U.S. until 2037—providing pediatric exclusivity is granted.
September 12, 2025
·
2 min read
·
Tristan Manalac
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
August 25, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
AbbVie Reports Third-Quarter 2025 Financial Results
October 31, 2025
·
28 min read
Press Releases
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals’ Bretisilocin
October 20, 2025
·
3 min read
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
AbbVie’s Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who have received prior lines of treatment.
May 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
October 1, 2025
·
2 min read
Drug discovery
AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal
The ADARx Pharmaceuticals partnership, which could be worth “several billion dollars” in the end, adds to AbbVie’s existing work in the space after the $1.4 billion acquisition of Aliada Therapeutics in October 2024.
May 14, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
AbbVie’s VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta
September 16, 2025
·
4 min read
1 of 71,386
Next
